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Pharmacological doses of ascorbate were evaluated for its ability to potentiate the toxicity of sodium
orthovanadate (Na3VO4) in tumor cells. Cytotoxicity, inhibition of cell proliferation, generation of ROS
and DNA fragmentation were assessed in T24 cells. Na3VO4 was cytotoxic against T24 cells (EC50 = 5.8 lM
at 24 h), but in the presence of ascorbate (100 lM) the EC50 fell to 3.3 lM. Na3VO4 plus ascorbate caused a
strong inhibition of cell proliferation (up to 20%) and increased the generation of ROS (4-fold). Na3VO4 did
not directly cleave plasmid DNA, at this aspect no synergism was found occurring between Na3VO4 and
ascorbate once the resulting action of the combination was no greater than that of both substances
administered separately. Cells from Ehrlich ascites carcinoma-bearing mice were used to determine
the activity of antioxidant enzymes, the extent of the oxidative damage and the type of cell death.
Na3VO4 alone, or combined with ascorbate, increased catalase activity, but only Na3VO4 plus ascorbate
increased superoxide dismutase activity (up to 4-fold). Oxidative damage on proteins and lipids was
higher due to the treatment done with Na3VO4 plus ascorbate (2–3-fold). Ascorbate potentiated apoptosis
in tumor cells from mice treated with Na3VO4. The results indicate that pharmacological doses of ascor-
bate enhance the generation of ROS induced by Na3VO4 in tumor cells causing inhibition of proliferation
and apoptosis. Apoptosis induced by orthovanadate and ascorbate is closer related to inhibition on Bcl-xL
and activation of Bax. Our data apparently rule out a mechanism of cell demise p53-dependent or related
to Cdk2 impairment.
 2012 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
Vanadium salts may be promising for anticancer therapy. They
present cytotoxicity against several types of human tumor cell
lines. Earlier reports have demonstrated that subcutaneous injec-
tions of orthovanadate into mice bearing a highly metastatic mur-
ine lymphosarcoma MDAY-D2 triggered signiﬁcant reduction ofBioquímica Experimental –
cias Biológicas, Universidade
is, SC, Brazil. Fax: +55 483721
za@ccb.ufsc.br (R.C. Pedrosa).
sevier OA license. tumor growth [1–3]. Multiple biochemical and molecular actions
of vanadium have been associated with its antitumor properties
[4]. It is well-known that it can act on the apoptotic process by
modulating the extent and duration of phosphorylation on a great
variety of key-proteins from cell signaling mediated by reactive
oxygen species (ROS) and DNA damage [5]. Evidence demonstrates
the possible involvement of vanadium in redox reactions associ-
ated with ROS generation that can culminate in cell cycle arrest
at the G2/M phase and cell death [6,7].
Exogenously added compounds containing orthovanadate or
vanadium (5+ or V) can permeate the cancer cells, where they
are reduced to vanadyl (4+ or IV) consuming reducing agents com-
mon to cells such as ascorbate and glutathione [8]. The reaction
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suggest that vanadyl can also react with O2 yielding H2O2, hydroxyl
radicals and related oxygen species [9,10].
Cancer cells often exhibit high levels of ROS and low antioxi-
dant defense activity [11]. Due to an overexpression of GLUT
transporters, cancer cells may increase the uptake and accumu-
late ascorbate [12,13]. Thus, in this study, we explored this
vulnerability (high ROS and low antioxidant defenses) by
evaluating the administration of sodium orthovanadate, alone or
combined with pharmacological doses of ascorbate. We hypothe-
sized that ascorbate, by impairing the cancer cells redox status,
can potentiate orthovanadate antitumor activities, leading them
to a loss of cell growth capability and/or to cell death. Thus, we
evaluated the type of cell death and whether orthovanadate
combined with ascorbate provokes increased cytotoxicity, ROS
generation, inhibition of proliferation and antitumor effects in
mice.2. Materials and methods
2.1. Chemicals and antibodies
Sodium orthovanadate, sodium ascorbate, N-acetylcystein
(NAC), catalase (CAT) and dichloroﬂuorescein diacetate (DCFH-
DA) were purchased from Sigma–Aldrich (St. Louis, MO, USA). Dul-
becco’s modiﬁed Eagle’s medium (DMEM), fetal bovine serum
(FBS), antibiotics and other cell culture material were obtained
from Cultilab (São Paulo, Brazil). The kit for apoptosis detection
containing annexin V-FITC and propidium iodide was from BD
Pharmingen (San Diego, CA, USA). Rabbit polyclonal antibody
against P53 and cyclin-dependent kinase 2 (Cdk2) and mouse poly-
clonal antibody against Bcl-xL and Bax were from Santa Cruz Bio-
technology Inc. (USA). Mouse antibody against b-actin, the
secondary antibodies and the kit for chemiluminescence detection
of HRP-coupled antibodies were from Millipore (USA). All other
products were from ACS analytical grade reagents.2.2. In vitro assays
Human bladder carcinoma-derived T24 cells were obtained
from the Rio de Janeiro cell bank, Brazil. Cells were grown in
DMEM supplemented with FBS 10%, penicillin 100 U/mL and strep-
tomycin 100 lg/mL. Cytotoxicity was assessed by the MTT assay as
described by Mosmann [14]. Adhered cells (104) in 96-well plates
were exposed for 24 h to medium containing ascorbate up to
100 lM or orthovanadate (0.5–10 lM) separately or combined.
Fresh medium was utilized for the negative controls. Three inde-
pendent experiments were done and the results were presented
in the form of EC50.
Cell proliferation was evaluated according to Franken et al. [15].
Cells were seeded at single cell density (500) in 6-well plates, and
after adherence they were treated respectively. They were then
washed twice and fresh medium was added. After 10 days, cells
were ﬁxed and stained by crystal violet. Colonies with more than
50 cells were counted.
Intracellular ROS were evaluated as reported by Kviecinski et al.
[16]. Cells (15.000) were loaded with 10 lM DCFH-DA in HBSS and
incubated for 30 min. Excess DCFH-DA was removed by washing
with fresh HBSS. Cells were then incubated for 2 h with the test
compounds, washed twice more with HBSS, and then 100 lL of
HBSS/well was added. Fluorescence was measured with a micro-
plate reader (Victor™ 2, PerkinElmer) at 485 nm for excitation
and at 530 nm for emission. Changes in ROS levels were deter-
mined by calculating DF = (F  F0)/F0, where F represents the ﬂuo-
rescence read at each time point and F0 the control ﬂuorescence.DNA fragmentation was evaluated as reported by Rey et al. [17].
Plasmid DNA (600 ng) in HEPES buffer 20 mM (pH 7.4) was ex-
posed for 16 h at room temperature to orthovanadate (10 lM) or
ascorbate (100 lM) separately or combined. EcoRI 50kU (1 lL)
was utilized for the positive controls. Samples were then submit-
ted to agarose gel electrophoresis and stained with ethidium bro-
mide, from which we obtained bands that represented the proﬁle
of a breach in DNA. Bands were quantiﬁed by densitometry analy-
sis using Image J 1.30 software (NIH, USA).
Western blots were performed as described by Dejeans et al.
[18], using whole cells protein homogenates from treated with
orthovanadate (5 lM) or ascorbate (1 mM) separately or combined
for 6 h. Control conditions represented protein homogenates from
non-treated cells. Equal amounts of protein (20 lg) were subjected
to SDS–PAGE followed by electroblot to PVDF membranes. Mem-
branes were incubated with the primary antibodies and further
incubated with the secondary ones. Immune detection was done
using a chemiluminescence kit for HRP-coupled antibodies. b-Actin
served as a loading control.2.3. In vivo antitumor activity
Male BALB/c inbred mice (20–22 g) were kept, receiving water
and food ad libitum. Procedures were done in accordance with legal
requirements (NIH publication #80-23, revised in 1978) and with
the approval of the local ethics committee. Previous tests were
done to select the maximal safe doses of orthovanadate, afterwards
ascorbate was administered at 10-fold higher the dose of orthovan-
adate. On Day zero, Ehrlich carcinoma cells (5  106) were inocu-
lated i.p. into mice from four groups (n = 12). i.p. treatments
were done every 24 h for 9 days. Control animals receiving saline
i.p. injections. Test groups received orthovanadate (18.75 mg/kg)
or ascorbate (187.5 mg/kg). The last group received both orthovan-
adate and ascorbate in combination. On the tenth day, six mice
from each group were euthanized. The inhibition on tumor growth
was found taking into consideration the change in the abdominal
circumference measured on days 0 and 10 [19]. Peritoneal cell sus-
pensions were collected to determine oxidative stress markers and
type of cell death. The remaining animals were kept alive to eval-
uate parameters of survival. The percentage of increased life span
was calculated by recording the mortality on a daily basis for
30 days according to Mazumdar et al. [20] as follows:
Mean survival time ðMSTÞ ¼ day of the first death
þ day of the last death=2 ð1ÞILS ð%Þ ¼ ½ðMST of treated group=MST of control groupÞ1 100
ð2Þ2.4. Oxidative stress in tumor tissue
Catalase activity was determined kinetically through the meth-
od described by Aebi [21] based on the decomposition of H2O2 and
the decrease in absorbance at 240 nm. Superoxide dismutase (SOD)
activity was measured monitoring the oxidation of adrenaline to
adrenochrome as described by Misra and Fridovich [22]. Oxidative
damage to proteins was quantiﬁed as carbonyl proteins as origi-
nally described by Levine et al. [23]. Carbonyl groups from proteins
in the sample react covalently with 2,4-dinitrophenylhydrazine in
acid, which leads to the formation of a 2,4-dinitrophenylhydrazone
product. The reaction was followed by spectrophotometric quanti-
ﬁcation of the acid hydrazones at 370 nm. Lipid peroxidation was
estimated by measurement of malondialdehyde formation using
the thiobarbituric acid method, as described by Okawa et al. [24].
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2.5. Type of tumor cell death in vivo
Tumor cells obtained from the peritoneal cavity of mice were
washed (106) and treated with a binding buffer 100 lL (10 mM
Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2), and Annexin
V-FITC (2 lL) and propidium iodide (2 lL) were added using a kit
from BD Pharmingen (San Diego, CA, USA) according to the manu-
facturer’s instructions. Flow cytometric analysis was performed
immediately after cell labeling. Data acquisition and analysis were
performed in a Becton Dickinson FACSCalibur ﬂow cytometer using
CellQuest software. Another 5  106 cells washed in PBS (1 mL)
were treated with a dye solution (1 ll) containing ethidium bro-
mide 100 lg/mL and acridine orange 100 lg/mL (1:1). These cells
were observed on slides under a ﬂuorescence microscope. For each
sample 300 cells were counted in triplicate. They were photo-
graphed for a visual record. The results were expressed as a per-
centage of viable, apoptotic and necrotic cells [26].
2.6. Statistical analysis
In vitro assays were repeated three times independently. Bio-
chemical assays were done in triplicate. Results expressed as
mean ± standard deviation. Data were analyzed with the ANOVA
test followed by the Bonferroni test. Comparisons and the EC50 val-
ues were done using GraphPad Prism software (San Diego, USA).
Values of p < 0.05 were considered to be statistically signiﬁcant.
3. Results and discussion
There is special attention on vanadium salts due to their cyto-
toxicity. Vanadium is truly bioactive by modifying xenobioticFig. 1. Na3VO4 plus ascorbate (Asc) caused increased inhibition of cell proliferation (A) a
N-acetylcystein (NAC) or catalase (CAT) can restrict ROS formation. () and () denoteenzymes, inhibiting tyrosine phosphatases, and at the same time,
activating phosphorylases triggering a number of cellular meta-
bolic pathways, which can lead to cell death mainly through apop-
tosis [4,27]. The results of the MTT assay reveal that orthovanadate
increased T24 cells death in a concentration-dependent manner,
whereas ascorbate up to 100 lM did not induce cytotoxicity. Con-
sequently, the EC50 value estimated at 24 h for orthovanadate was
5.8 lM. Orthovanadate, when administrated in combination with
100 lM ascorbate presented decreased EC50 equivalent to 3.3 lM.
Evidence from literature also indicates that vanadium com-
pounds can exert antiproliferative effects mainly through cell cycle
arrest [6,7]. Fig. 1(A) shows that orthovanadate reduced in a con-
centration-dependent manner the proliferation of T24 cells. The
treatments done only with ascorbate up to 100 lM did not affect
cell proliferation. Contrarily, the addition of ascorbate to orthovan-
adate-treated cells resulted in a strong inhibition of cell growth as
shown in Fig. 1(A).
As explained in the introduction section, some evidence indi-
cates that within cells, vanadium V may be reduced by cellular
electron donors such as ascorbate, thereby inducing ROS forma-
tion [8–10]. Data showed in Fig. 1(B) demonstrates the formation
of ROS suggesting a role of free radicals in orthovanadate–
ascorbate toxicity. Here it is possible to verify that the addition
of ascorbate to orthovanadate-treated cells in culture increased
by about 4-fold the content of intracellular ROS, whereas the anti-
oxidants NAC or CAT decreased in a substantial way the forma-
tion of ROS.
A previous study indicated that vanadium compounds induce
DNA cleavage, not directly reacting with DNA but acting through
the production of ROS [7]. Fig. 1(C) shows the integrity of plasmid
DNA which was estimated from its electrophoretic mobility under
the different experimental conditions. FI represented the predom-
inant intact form of DNA as observed in control conditions,
whereas DNA treated by EcoRI was cleaved presenting alterednd generation of intracellular ROS (B) but did not directly cleave plasmid DNA (C).
difference at p < 0.05 and p < 0.001 between indicated treatments.
Fig. 2. Na3VO4 plus ascorbate (Asc) caused increased inhibition on tumor growth.
The animals under this treatment lived more. () and () denote difference at
p < 0.01 and p < 0.001 compared to the negative control (NEG) or between indicated
treatments.
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served no differences between control and orthovanadate trea-
ted-DNA plasmids. In addition, these data indicated that no
synergism is occurring between orthovanadate and ascorbate.
Indeed, the DNA cleaving effect of both products administered
together was not greater than the effects of the products adminis-
tered separately (Fig. 1C).
Years ago, vanadium tested along with other metals was inac-
tive against spontaneous mice tumors [28]. However, experiments
carried out during the last two decades have demonstrated that
orthovanadate and various peroxovanadates actually exert signiﬁ-
cant anticancer effects on tumor bearing mice [3,29,30]. Fig. 2Fig. 3. Na3VO4 alone and combined with ascorbate (Asc) increased catalase activity (A)
Oxidative damage on proteins (C) and lipids (D) was higher due to the treatment done wi
p < 0.001, respectively compared to the negative control (NEG) or between indicated treshows that Na3VO4 inhibited Ehrlich ascites carcinoma prolifera-
tion and enhanced the survival of mice. Very interestingly, this ef-
fect was more than 2-fold higher when we combined with
ascorbate at a pharmacological dose. The inoculation (i.p.) of Ehr-
lich carcinoma in saline-treated mice resulted in regular develop-
ment of ascites ﬂuid. As illustrated in Fig. 2, the treatment done
only with ascorbate was unable to produce a considerable differ-
ence neither in terms of tumor growth inhibition nor ILS. Animals
treated with orthovanadate showed approximately 50% reduction
in the tumor growth on average in comparison to saline-treated
animals (open bars). Interestingly, the inhibition was superior by
up to 80% when the animals’ treatment combined orthovana-
date–ascorbate. Animals treated with orthovanadate lived more
than saline-treated mice presenting ILS of about 20% (closed bars).
However, the animals that received orthovanadate combined with
ascorbate lived about 35% more than animals from the control
group (Fig. 2).
Previous studies have already shown that administration of
vanadium salts to mouse epidermal cells induced apoptosis
through the production of H2O2 and other ROS, which in turn, acti-
vated p53 [31,32]. Once we conﬁrmed that the administration of
ascorbate to orthovanadate-treated tumor bearing mice resulted
in an increased survival, we decided to monitor ROS generation
and some oxidative markers in vivo, also evaluating the dying tu-
mor cells trying to differentiate them according to the type of
death. Data shown in Fig. 3 relate to the effects of orthovanadate
alone or with ascorbate on some oxidative markers here measured
in cellular suspensions from mice peritoneal cavity. By looking
Fig. 3, a similar proﬁle for all the markers was observed. Increased
activity of catalase and superoxide dismutase (Fig. 3A/B) plusbut only Na3VO4 plus ascorbate increased superoxide dismutase (SOD) activity (B).
th Na3VO4 plus ascorbate. (), () and () denote difference at p < 0.05, p < 0.01 and
atments.
Fig. 4. Ascorbate (Asc) potentiated apoptosis in tumor cells from mice treated with Na3VO4 as indicated by the increase in annexin V-FITC positive cells (A) and cells with
bright green nucleus and condensed or fragmented chromatin double stained with acridine orange and ethidium bromide (B). Orthovanadate plus ascorbate inhibits Bcl-xL
and apparently activates Bax, whereas P53 and Cdk2 are not modiﬁed by the treatments (C).
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(Fig. 3C/D) we detected in samples of tumors in remission from
mice treated with orthovanadate. This reinforced that an oxidative
stress does occur in vivo. Once again the addition of ascorbate to
orthovanadate resulted in a 2–3-fold increase on average in oxida-
tive markers compared to samples from only orthovanadate-trea-
ted mice.
In the ideal anticancer therapy, the drugs would be able to spe-
ciﬁcally target the cancer cells. Identifying cell-speciﬁc inducers of
apoptosis is a great challenge. In order to assess the demise of Ehr-
lich cells triggered by orthovanadate–ascorbate in vivo, we per-
formed two assays reﬂecting the cell membrane integrity and
phosphatidylserine translocation by a double Annexin-V and pro-
pidium iodide staining (Fig. 4). Both results conﬁrm that orthovan-
adate can actually lead cells to apoptosis, although the
combination orthovanadate–ascorbate can kill more cells than
orthovanadate alone. The increased occurrence of dying cells in
Quadrant 4 suggests the presence of cells mainly in early and
mid-stage apoptosis (Fig. 4A). Apoptosis occurred in cancer cells
from mice treated with orthovanadate very possibly because
orthovanadate triggered ROS over production. We found impair-
ment to cell proliferation as well. Nevertheless, considering the
data in Fig. 4, ascorbate potentiates apoptosis caused by
orthovanadate.
The step of decision of apoptosis is controlled by the genes Bcl-2
and p53. Bcl-2 proteins regulate apoptosis on mitochondria mem-
branes and endoplasmic reticulum; they can act on the calcium
channels. Proteins such as Bcl-2 and Bcl-xL prevent apoptosis,
whereas X protein-associated Bcl-2 such as Bax, Bak and Bcl-xS
promote it [33]. Data illustrated in Fig. 4(C) show that the treat-
ments with orthovanadate and ascorbate had little effect on Bax,
but Bcl-xL was clearly inhibited. Recently, Morita et al. [34] dem-
onstrated that apoptosis mediated by p53 can be inhibited byorthovanadate. However, our data show that vanadate induces
apoptosis potentiated by ascorbate, probably due to a mechanism
p53-independent. Indeed, data in Fig. 4(C) conﬁrm that p53 was
not affected either by vanadate alone or by its association with
ascorbate. Moreover, according to data in Fig. 4(C), it seems that
the mechanism of apoptosis induced by vanadate and ascorbate
does not include actions on Cdks. Actually the bands corresponding
to Cdk2 from cells treated with vanadate and/or ascorbate were
not different from that of the controls either.
Assuming that cancer cells are taking up more ascorbate than
normal cells [12,13], this study showed evidence that encourages
the development of a novel way to explore vanadium antitumor
properties by favoring its selectivity.
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